Monoamine neurotransmitter pathway

The monoamine pathway is a complex biological network involved in the synthesis, release, reuptake, and degradation of biogenic amines, including dopamine, serotonin, norepinephrine, epinephrine, and histamine. These neurotransmitters are derived from aromatic amino acids like tyrosine and tryptophan through the action of rate-limiting enzymes such as tyrosine hydroxylase and tryptophan hydroxylase (StatPearls, 2023; NIH, 2022). The pathway is central to the regulation of numerous physiological and cognitive processes, including mood, reward, attention, and autonomic functions. Dysregulation of monoamine signaling is a hallmark of many neuropsychiatric and neurological disorders, such as major depressive disorder, schizophrenia, and Parkinson's disease (PubMed, 2021). Pharmacological intervention in this pathway is a cornerstone of modern psychiatry and neurology, utilizing drugs that modify neurotransmitter levels or receptor activity to restore equilibrium. However, because these transmitters are widely distributed throughout the central and peripheral nervous systems, drugs targeting this pathway often carry risks of systemic side effects, such as cardiovascular changes or movement disorders (Wikipedia, 2023).

Other names

Monoaminergic systemMonoamine metabolism pathwayBiogenic amine pathwayMonoaminergic signaling pathway

Drugs targeting this pathway typically act via reuptake inhibition (blocking transporters like SERT, DAT, or NET), enzymatic inhibition (blocking MAO or COMT), or through direct agonism/antagonism of specific monoamine receptors (e.g., D2, 5-HT2A).